Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Dual IDH1/2 inhibitor

Vorasidenib (Specialist drug)

Brand names: Voranigo

Vorasidenib is an oral inhibitor of mutant isocitrate dehydrogenase used in the treatment of certain IDH-mutated gliomas.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the mutant IDH1 and IDH2 enzymes, reducing production of the oncometabolite 2-hydroxyglutarate that promotes tumour growth.

Prescribing in practice

  • Hepatotoxicity, including raised transaminases, can occur and requires baseline and ongoing liver function monitoring.
  • A confirmed IDH1 or IDH2 mutation should be present before treatment.
  • It is a specialist oncology medicine initiated and supervised by clinicians experienced in neuro-oncology.

Monitoring

Monitor liver function tests regularly throughout treatment as directed by the SPC.

Counselling the patient

  • Report symptoms suggesting liver problems such as jaundice, dark urine or abdominal pain.
  • Take the medicine as directed and attend scheduled blood tests.
  • Tell the team about all other medicines, as interactions can occur.

Evidence & guidelines

Use is informed by the INDIGO trial in residual or recurrent IDH-mutant grade 2 glioma.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways